Medgenics to Present at the 10th Annual ILSI Biomed 2011 Conference
May 19 2011 - 8:00AM
Business Wire
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG)
today announced that Andrew L. Pearlman, Ph.D., the Company’s
President and CEO, will present a corporate overview at the 10th
Annual Israeli Life Sciences Industry Biomed 2011 Conference taking
place at the David Intercontinental & Dan Panorama Hotels in
Tel Aviv, Israel from May 23-25, 2011. Dr. Pearlman will deliver
the Company’s presentation on Monday, May 23 at 4:30 p.m. (local
time) in Hall B.
ILSI-Biomed 2011 follows the success of its previous annual
conferences: last year’s event drew 6,000 industry professionals,
engineers and scientists, with 1,000 participants from 42 countries
and more than 2,500 one-on-one meetings. This provides Medgenics
with significant opportunity to showcase before a global audience
of relevant industry leaders its novel, tissue-based technology
platform, the Biopump, for the sustained production and dosing of
therapeutic proteins using a patient’s own tissue.
About Israeli Life Sciences Industry
The Israel Life Science Industry (ILSI) is composed of medical
device, biotechnology, pharmaceutical and medical service
companies, universities and private research institutions, and
providers of services to the industry such as venture capitalists,
lawyers, accountants and incubators. The goal of ILSI is to develop
solid information about the medical research and manufacturing
community in Israel, and to make that information available to
political leaders, the news media, venture capitalists, investment
bankers, and the public. It is exactly this information required by
potential investors be it strategic corporate players or financial
investors worldwide. The intent is to demonstrate that medical
research and manufacturing is a major contributor to Israel’s
economy - with unusually great potential for financial growth and
job creation.
About Medgenics
Medgenics is developing and commercializing Biopump, a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient’s
own skin biopsy for the treatment of a range of chronic diseases
including anemia, hepatitis C and hemophilia. Medgenics believes
this approach has multiple benefits compared with current
treatments, which include regular and costly injections of
therapeutic proteins.
Medgenics has three long-acting protein therapy products in
development based on this technology:
- EPODURE (now completing a Phase I/II
dose-ranging trial) to produce and deliver erythropoietin for many
months from a single administration, has demonstrated elevation and
stabilization of hemoglobin levels in anemic patients for 6-28
months;
- INFRADURE (to commence a Phase I/II
trial in Israel in 2011) to produce a sustained therapeutic dose of
interferon-alpha for use in the treatment hepatitis C;
- HEMODURE is a sustained Factor VIII
therapy for the prophylactic treatment of hemophilia, now in
development in collaboration with Medgenics’ first major
pharmaceutical partner, a market leader in hemophilia.
Medgenics intends to develop its innovative products and bring
them to market via strategic partnerships with major pharmaceutical
and/or medical device companies. In addition to treatments for
anemia, hepatitis C and hemophilia, Medgenics plans to develop
and/or out-license a pipeline of future Biopump products targeting
the large and rapidly growing global protein therapy market, which
is forecast to reach $132 billion in 2013. Other potential
applications for Biopumps include multiple sclerosis, arthritis,
pediatric growth hormone deficiency, obesity and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend,"
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Oct 2023 to Oct 2024